(Q35562606)

8 August 2017

title

Dutasteride. (English)

1 reference

8 August 2017

Hannah C Evans

1

1 reference

8 August 2017

Karen L Goa

series ordinal

2

1 reference

8 August 2017

publication date

1 January 2003

1 reference

8 August 2017

1 reference

8 August 2017

volume

20

1 reference

8 August 2017

issue

12

1 reference

8 August 2017

page(s)

905-16; discussion 917-8

1 reference

Mechanism of Time-Dependent Inhibition of 5.alpha.-Reductases by .DELTA.1-4-Azasteroids: Toward Perfection of Rates of Time-Dependent Inhibition by Using Ligand-Binding Energies

8 August 2017

cites work

1 reference

12 December 2020

Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia

1 reference

12 December 2020

Benign prostatic hyperplasia. Practical treatment guidelines

1 reference

12 December 2020

Treatment of benign prostatic hyperplasia. A pharmacoeconomic perspective

1 reference

12 December 2020

Finasteride: an update of its use in the management of symptomatic benign prostatic hyperplasia

1 reference

12 December 2020

A model for the turnover of dihydrotestosterone in the presence of the irreversible 5 alpha-reductase inhibitors GI198745 and finasteride

1 reference

12 December 2020

Discovery and development of GG745, a potent inhibitor of both isozymes of 5 alpha-reductase

1 reference

12 December 2020

Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor

1 reference

12 December 2020

Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR

1 reference

12 December 2020

The pharmacokinetic modelling of GI198745 (dutasteride), a compound with parallel linear and nonlinear elimination

1 reference

12 December 2020

Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia

1 reference

12 December 2020

Alpha-adrenoceptor antagonists in the treatment of benign prostatic hyperplasia

1 reference

12 December 2020

Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor

1 reference

12 December 2020

10.2165/00002512-200320120-00005

Identifiers

DOI

1 reference

Dimensions Publication ID

8 August 2017

1034780460

0 references

1 reference